Literature DB >> 33566584

Effects of Charged Oxime Reactivators on the HK-2 Cell Line in Renal Toxicity Screening.

Jiri Handl1, David Malinak2, Jan Capek1, Rudolf Andrys2, Erika Rousarova1, Martina Hauschke1, Lenka Bruckova1, Petr Cesla3, Tomas Rousar1, Kamil Musilek2.   

Abstract

Oxime cholinesterase reactivators (oximes) are used to counteract organophosphate intoxication. Charged oximes are administered via intramuscular or intravenous injection when the majority of dose is unmetabolized and is excreted as urine. In this study, the effects of selected double charged oximes were determined in the HK-2 cell line as a model for renal toxicity screening. Some effects on dehydrogenase activity were found for obidoxime, asoxime (syn. HI-6), K027, and K203. The effects of K868 and K869 were found to be unreliable due to rapid degradation of both chlorinated oximes in the assay medium, resulting for K868 in an isoxazole-pyridinium product.

Entities:  

Year:  2021        PMID: 33566584     DOI: 10.1021/acs.chemrestox.0c00489

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  2 in total

1.  Charged pyridinium oximes with thiocarboxamide moiety are equally or less effective reactivators of organophosphate-inhibited cholinesterases compared to analogous carboxamides.

Authors:  Zuzana Kohoutova; David Malinak; Rudolf Andrys; Jana Svobodova; Miroslav Psotka; Monika Schmidt; Lukas Prchal; Kamil Musilek
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

2.  Evaluating the Use of TiO2 Nanoparticles for Toxicity Testing in Pulmonary A549 Cells.

Authors:  Jana Bacova; Petr Knotek; Katerina Kopecka; Ludek Hromadko; Jan Capek; Pavlina Nyvltova; Lenka Bruckova; Ladislava Schröterova; Blanka Sestakova; Jiri Palarcik; Martin Motola; Dana Cizkova; Ales Bezrouk; Jiri Handl; Zdenek Fiala; Emil Rudolf; Zuzana Bilkova; Jan M Macak; Tomas Rousar
Journal:  Int J Nanomedicine       Date:  2022-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.